Provider review
Mochi Health tirzepatide review
What Mochi Health charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
This is an independent assessment of Mochi Health's tirzepatide program against our published 100-point rubric. It separates what the provider states from what we verified. No pricing, scoring or state data has been captured yet, so nothing below is presented as a finding. Verification status appears beside every field.
What is distinctive about this programme
Read the total, not the medication line
Mochi's advertised medication prices — $99 semaglutide and $199 tirzepatide — are among the lowest anywhere. The required $79 monthly membership makes the actual totals $178 and $278, which places the programme mid-table rather than at the top.
This is the clearest example in our dataset of why we publish totals. A comparison ranking on the medication column alone would place Mochi first for semaglutide; on the total it sits eighth.
What the membership buys
Unlimited physician and dietitian access is a substantive inclusion rather than a platform fee. At $948 a year it is not cheap, but a patient who will actually use clinical and dietetic support is buying something real, and several cheaper all-inclusive competitors provide less contact.
The $39 first-month membership rate is an introductory price that rises to $79. We exclude introductory rates from every ranking on this site, because they apply to one month of an indefinite treatment.
Flat across doses
Price is reported as the same at all doses, which removes escalation risk. Commitment tiers are reported to reduce the membership component.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $178 | Reported |
| Tirzepatide injectable | $278 | Reported |
Where it holds up
- Same price at all doses, removing escalation risk
- Membership includes unlimited physician and dietitian access, not just platform access
- Commitment tiers reduce the membership component
- Medication pricing is genuinely low before the membership
Where it does not
- Membership is required, and it roughly doubles the semaglutide medication price
- The $39 first-month membership is introductory and rises to $79
- Total cost places the programme mid-table despite a market-leading medication price
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $178/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
Show this figure as a table
| Item | Points | Evidence |
|---|---|---|
| Pricing transparency and all-in value | 25 pts | Verified |
| Clinical oversight and care continuity | 20 pts | Verified |
| Pharmacy traceability and quality disclosures | 15 pts | Verified |
| Regulatory clarity and consumer disclosures | 15 pts | Verified |
| State access and operational reliability | 10 pts | Verified |
| Cancellation, billing and support transparency | 10 pts | Verified |
| Evidence quality and data availability | 5 pts | Verified |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Mochi Health | month_to_month | compounded injectable | — | $278 | — | $278 | Recurring | Reported | 2026-07-06 |
| Mochi Health | month_to_month | compounded injectable | — | $178 | — | $178 | Recurring | Reported | 2026-07-06 |
How this sits against the market
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Found | $169 | Reported |
| NexLife (opens nexlife.us in a new tab) | $186 | Verified |
| NexLife (opens nexlife.us in a new tab) | $190 | Verified |
| NexLife | $195 | Verified |
| NexLife | $215 | Verified |
| Shed | $245 | Reported |
| Mochi Health | $278 | Reported |
| Enhance.MD | $280 | Reported |
| Eden | $298 | Reported |
| Noom Med | $299 | Reported |
| TrimRx | $349 | Reported |
| MEDVi | $399 | Pending |
| bmiMD | $399 | Reported |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | — |
| Shipping | no | — |
| Higher-dose surcharge | no | — |
| Initial consultation | no | — |
| Required laboratory work | no | — |
| Cancellation or restocking terms | no | — |
A dash means no figure held. How we grade evidence.
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Clinical model
Pharmacy and fulfilment
Billing, cancellation and support
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Mochi Health sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered Pending |
| Clinical oversight and care continuity | 20 pts | — | Not answered Pending |
| State access and operational reliability | 10 pts | — | Not answered Pending |
| Cancellation, billing and support transparency | 10 pts | — | Not answered Pending |
A dash means no figure held. How we grade evidence.
Questions readers actually ask
Is Mochi Health the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. No provider pays for coverage, placement, a score or a link, and providers do not see a review before it publishes.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Eden Tirzepatide ReviewProviders
- The Hidden Cost of GLP-1 Membership FeesJournal
- NexLife vs Mochi HealthComparisons
Related coverage
- MEDVi Tirzepatide Review
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List
- Comment Period on the GLP-1 Bulks Proposal Extended to 30 July
- FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products
- FDA Panel Recommends Six of Seven Peptides for Compounding, Overriding Its Own Scientists
- FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week
- FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Loss
Tirzepatide Ranked. “Mochi Health Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/mochi-health/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 15 of 70 price records in this dataset were read at the source by us: 9 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.